25 / 43
EXTREME: Baja incidencia de toxicidad durante CTX
de mantenimiento
*Treatment-emergent AEs that were ongoing or started after end of CT
and within 30 days after end of cetuximab.
†
According to ‘Skin and subcutaneous tissue disorders’ system organ class.
Included rash, acne, dry skin, alopecia, pruritus, dermatitis acneiform,
exfoliative rash.
Vermorken JB, et al. Poster presented at ASCO 2014
(Abstract No. 6021)
0
5
10
15
20
25
30
35
40
Grade 3/4 AEs (%)
Cetuximab + CT treatment phase (n=100)
Grade 3 and 4 AEs with a frequency >5% in either phase